0.572
price up icon0.07%   0.0004
after-market Handel nachbörslich: .57 -0.002 -0.35%
loading
Schlusskurs vom Vortag:
$0.5716
Offen:
$0.609
24-Stunden-Volumen:
217.23K
Relative Volume:
0.07
Marktkapitalisierung:
$4.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.28M
KGV:
-0.1029
EPS:
-5.56
Netto-Cashflow:
$-7.99M
1W Leistung:
-13.33%
1M Leistung:
-13.60%
6M Leistung:
-12.80%
1J Leistung:
-87.12%
1-Tages-Spanne:
Value
$0.5653
$0.609
1-Wochen-Bereich:
Value
$0.5636
$0.6548
52-Wochen-Spanne:
Value
$0.425
$6.18

Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile

Name
Firmenname
Quoin Pharmaceuticals Ltd Adr
Name
Telefon
97299741444
Name
Adresse
23 HATA'AS STREET, KFAR SABA
Name
Mitarbeiter
4
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
QNRX's Discussions on Twitter

Vergleichen Sie QNRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
QNRX
Quoin Pharmaceuticals Ltd Adr
0.572 4.68M 0 -8.28M -7.99M -5.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
411.66 106.01B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
690.87 75.92B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.60 39.80B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.51 31.02B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.43 26.95B 3.30B -501.07M 1.03B -2.1146

Quoin Pharmaceuticals Ltd Adr Aktie (QNRX) Neueste Nachrichten

pulisher
Jan 14, 2025

Quoin reports progress in pediatric skin disorder study - Investing.com

Jan 14, 2025
pulisher
Jan 07, 2025

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire Inc.

Jan 07, 2025
pulisher
Jan 06, 2025

Quoin Pharmaceuticals reports positive trial results for skin treatment - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Quoin reports positive results in Netherton Syndrome study - Investing.com

Jan 06, 2025
pulisher
Dec 28, 2024

Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares - Investing.com India

Dec 28, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares By Investing.com - Investing.com South Africa

Dec 27, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares - Investing.com India

Dec 27, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares - Investing.com India

Dec 27, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares By Investing.com - Investing.com South Africa

Dec 27, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares By Investing.com - Investing.com South Africa

Dec 27, 2024
pulisher
Dec 27, 2024

Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares By Investing.com - Investing.com South Africa

Dec 27, 2024
pulisher
Dec 20, 2024

Quoin Pharmaceuticals sets terms for public offering - Investing.com

Dec 20, 2024
pulisher
Dec 19, 2024

Quoin Pharmaceuticals advances Netherton Syndrome study - Investing.com India

Dec 19, 2024
pulisher
Dec 11, 2024

Quoin Pharmaceuticals amends shareholder rights, adjusts executive compensation - Investing.com India

Dec 11, 2024
pulisher
Nov 07, 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results - Yahoo Finance

Nov 07, 2024
pulisher
Nov 05, 2024

Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com

Nov 05, 2024
pulisher
Oct 31, 2024

Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India

Oct 31, 2024
pulisher
Oct 22, 2024

Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com

Oct 22, 2024
pulisher
Sep 30, 2024

Quoin Pharmaceuticals sets date for 2024 shareholder meeting - Investing.com

Sep 30, 2024
pulisher
Sep 12, 2024

Balance Sheet Insights: Quoin Pharmaceuticals Ltd ADR (QNRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Sep 12, 2024
pulisher
Sep 12, 2024

Quoin Pharmaceuticals CFO buys shares worth over $23,000 - Investing.com

Sep 12, 2024
pulisher
Sep 11, 2024

Healthy Upside Potential: Quoin Pharmaceuticals Ltd ADR (QNRX) - SETE News

Sep 11, 2024
pulisher
Sep 10, 2024

A closer look at QNRX’s price-to-free cash flow ratio - US Post News

Sep 10, 2024
pulisher
Sep 05, 2024

Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Quoin Pharmaceuticals CEO acquires shares worth over $28k - Investing.com

Sep 05, 2024
pulisher
Aug 23, 2024

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Quotes, Forecast and News Summary - Benzinga

Aug 23, 2024
pulisher
Aug 02, 2024

QNRX Stock Hits 52-Week Low at $0.57 Amid Market Challenges - Investing.com Australia

Aug 02, 2024
pulisher
Mar 27, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 27, 2024
pulisher
Mar 26, 2024

GLMD Stock Quote Price and Forecast - CNN

Mar 26, 2024
pulisher
Mar 15, 2024

Earnings call: Quoin Pharmaceuticals reports Q4 progress and outlook By Investing.com - Investing.com South Africa

Mar 15, 2024
pulisher
Aug 05, 2022

Major Indexes Muted Following Strong Jobs Report - Schaeffers Research

Aug 05, 2022
pulisher
Jul 27, 2011

ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN

Jul 27, 2011

Finanzdaten der Quoin Pharmaceuticals Ltd Adr-Aktie (QNRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$30.03
price up icon 0.13%
$21.64
price down icon 0.37%
$71.93
price down icon 0.61%
$364.70
price up icon 0.50%
biotechnology ONC
$200.99
price up icon 8.87%
$112.43
price down icon 1.15%
Kapitalisierung:     |  Volumen (24h):